Continuation rate of hormone replacement therapy in Hong Kong public health sector
Continuation rate of hormone replacement therapy in Hong Kong public health sector
复制标题
DOI：
10.1016/j.maturitas.2004.03.010
复制
发表时间：
2004-12-10
期刊：
影响因子：
4.9
通讯作者：
Tang, GWK
中科院分区：
文献类型：
--
作者：
Leung, KY;Ling, M;Tang, GWK
目的：评估香港公共卫生部门规定的HRT的1年续行率，并找出影响该续行率的因素。方法：选择1998-01-2000-12期间在医院管理局36个专科门诊就诊的服用雌激素处方以上的妇女，观察至少2年，最多观察3年。从医院管理局的中央处方数据库中检索使用时间和变量，包括年龄、激素类型、给药途径、雌激素剂量和处方专业。结果：在12,711名HRT事件使用者中，超过一半的人年龄在50-59岁之间。大多数(78.5%)吸毒者服用结合型马类雌激素0.625 mg或相关产品。只有一小部分(3.0%)的女性使用CEE 0.3 mg。最初的雌激素处方是由妇科医生开的，占86.7%。总的1年续发率为68.3%。40-49岁的女性和两个极端年龄组(35-39岁和70-79岁)的续用率分别最高和最低。仅接受雌激素治疗的女性(如CEE或雌二醇)的续用率(总体为76.3%)高于使用持续联合治疗(58.6%)、序贯联合治疗(64.8%)或经皮雌激素(60.6%)的女性。在60-69岁年龄组，使用CEE0.3 mg比使用CEE 0.625 mg有更好的续用率。结论：年龄在60岁以下、口服HRT和子宫切除术的患者1年续发率较高。(C)2004爱思唯尔爱尔兰有限公司。保留所有权利。
Objectives: To assess the 1-year continuation rate of HRT prescribed in Hong Kong public health sector and to identify factors affecting this continuation rate. Methods: All women who received at least one dispensed prescription of estrogens between January 1998 and December 2000 from 36 specialist outpatient clinics of the Hospital Authority were selected, and observed for at least 2 years and at most 3 years. The duration of use and variables including age, types of hormones, routes of delivery, dose of estrogen, and prescribing specialty were retrieved from the central prescription database of the Hospital Authority. Results: Of 12,711 incident users of HRT, more than half were aged 50-59. Most (78.5%) of the users took conjugated equine estrogens (CEE) 0.625 mg or related products. Only a small proportion (3.0%) of women used CEE 0.3 mg. Initial estrogen prescriptions were written by gynaecologists in 86.7%. The overall 1-year continuation rate was 68.3%. The highest and lowest continuation rates were observed in women aged 40-49 and the two extreme age groups (35-39 and 70-79), respectively. Better continuation rate was observed in women taking estrogen-only therapy such as CEE or estradiol (overall 76.3%) than in women using continuous combined therapy (58.6%), sequential combined therapy (64.8%), or transdermal estrogen (60.6%). In the age group 60-69, the use of CEE 0.3 mg was associated with better continuation rate than CEE 0.625 mg. Conclusions: Better continuation rate at 1 year was associated with age younger than 60, oral route of HRT and hysterectomy. (C) 2004 Elsevier Ireland Ltd. All rights reserved.